French drugmaker Sanofi has teamed up with Brigham and Women’s Hospital (BWH) to collaborate on a new research programme focused on immunology of type 1 diabetes.
The two organisations have announced that they will investigate a novel target shown in pre-clinical studies to play significant role in treating type 1 diabetes.
Researchers from both Sanofi and BWH, a teaching and research affiliate of Harvard Medical School, will work together to identify potential drug candidates based on that target, which could offer a new ‘immunomodulatory’ approach for diabetes treatment.
Under the terms of the agreement, Sanofi will be able to exclusively license any products emerging from the collaboration.
Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi, said: “Our engagement in this important research collaboration exemplifies our aim to help identify new treatment options and ultimately bring real benefits to people with type 1 diabetes.
“By working together to translate academic knowledge into know-how about a potential new drug target, we hope to discover revolutionary new options for patients living with type 1 diabetes worldwide.”
